Drug Development for NASH with Fibrosis: Expedited Programs
Posted 30th July 2021 by Nicholas Noakes
George Makar spoke at the Global NASH Congress. He gave a regulatory perspective on Drug Development for NASH with Fibrosis. The views were his own. In part one, we explore expedited programs.
An Overview of Available Preclinical Models for Non-alcoholic Fatty Liver Disease
Posted 13th May 2020 by Liv Sewell
NASH is thought to affect 25% of the global population and is a primary risk factor for Hepatocellular carcinoma (HCC) – the second most common cause of cancer deaths worldwide. Understanding the aetiology of NAFLD progression, developing non-invasive diagnostic tests and developing treatments are urgent priorities.
Understanding the gut-liver axis: implications for NAFLD prevention and treatment
Posted 29th April 2020 by Liv Sewell
You may have heard; humans are superorganisms. The human large intestine harbors tens of trillions of microbes, which equates to roughly 2 kg of cells. For reference, that’s how much your brain weighs! Within the gut microbiome, it is estimated that there are over 1,000 different species of bacteria.
Novel biomarkers and the development of a point-of-care test for fatty liver disease
Posted 7th February 2020 by Liv Sewell
Ahead of The 3rd Global NASH Congress, Dr Bevin Gangadharan explains how he helped to discover novel NAFLD biomarkers and their role in the development of a point-of-care test for NAFLD.
Screening for NAFLD in primary care: a preventative wonder or are we barking up the wrong tree?
Posted 31st January 2020 by Joshua Sewell
The burden of chronic liver disease has a substantial health and economic burden within the UK. Chronic liver disease is the fifth most common cause of death in the UK and of those five, it is the only one with numbers that are rising. With this in mind, it would make sense that earlier detection of liver disease in primary care is key to improving outcomes and reducing costs.
Developing successful treatments for HCC and NASH
Posted 28th October 2019 by Liv Sewell
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the second most common cause of cancer deaths worldwide.[1] There is not currently a successful therapy to treat HCC in advanced stages.[2] NASH is a primary risk factor for liver cancer.
Devanand Sarkar and his team have uncovered the molecular mechanisms leading to NASH and HCC, shedding light on the connections between obesity and cancer. He is leveraging this knowledge to develop targeted treatments for both NASH and advanced HCC. We asked him to give us a brief insight into his work ahead of his presentation at the 3rd Global NASH Congress, 2020.
Understanding the Role of the Gut Microbiome in NAFLD
Posted 30th August 2019 by Liv Sewell
NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the reversible form of the disease is therefore a research priority. Recent work has shown perturbation of the microbiome and specific microbiome-associated metabolites contribute to the phenotype of NAFLD.
The EMA reflection paper on chronic liver disease and its implications for drug development in NASH
Posted 24th May 2019 by Joshua Sewell
The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in Autumn 2018. Elmer Schabel gives a detailed display of the contents of this first regulatory guidance with regard to NASH, as well as a preliminary evaluation of the initial feedback and input received by stakeholders.
